(Q43603050)

25 November 2017

title

Economic burden of HPV-related cancers in France (English)

1 reference

25 November 2017

1

0 references

Isabelle Borget

series ordinal

1

object named as

I Borget

1 reference

25 November 2017

L Abramowitz

2

1 reference

25 November 2017

P Mathevet

series ordinal

3

1 reference

25 November 2017

language of work or name

English

0 references

publication date

25 May 2011

1 reference

25 November 2017

number of pages

5

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

25 November 2017

volume

29

1 reference

25 November 2017

issue

32

1 reference

25 November 2017

page(s)

5245-5249

1 reference

The global health burden of infection-associated cancers in the year 2002

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.018

Chapter 2: The burden of HPV-related cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.018

Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.018

Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.018

Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973-2000.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.018

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.018

7 January 2021

HPV infection in Europe

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.018

Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.018

Estimates of cancer incidence and mortality in Europe in 2008.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.018

Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.018

Human papillomavirus prevalence and type distribution in penile carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.018

Human Papillomavirus Types in Head and Neck Squamous Cell Carcinomas Worldwide: A Systematic Review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.018

Human papillomavirus and oropharyngeal cancer: what you need to know in 2009.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.018

HPV-associated head and neck cancer: a virus-related cancer epidemic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.018

Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.018

Molecular classification identifies a subset of human papillomavirus--associated oropharyngeal cancers with favorable prognosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.018

Expression profiles of viral responsive genes in oral and oropharyngeal cancers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.018

Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.018

HPV & head and neck cancer: a descriptive update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.018

Economic burden of anal cancer management in France

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.018

Epidemiology and pathology of HPV disease in males

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.018

An analysis of temporal and generational trends in the incidence of anal and other HPV-related cancers in Southeast England.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.018

Awareness, knowledge, and beliefs about human papillomavirus in a racially diverse sample of young adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.018

Awareness of human papillomavirus in 23 000 Danish men from the general male population.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.018

Beyond cervical cancer: burden of other HPV-related cancers among men and women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.018

Cancer incidence and mortality in France over the period 1980–2005

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.018

Incidence of invasive cervical cancer and direct costs associated with its management in Italy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.018

Economic burden associated with the management of cervical cancer, cervical dysplasia and genital warts in Belgium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.018

Head and neck cancers in France: an analysis of the hospital medical information system (PMSI) database.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.018

Quality of life and head and neck cancer: a 5 year prospective study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.018

Swallowing dysfunction--preventative and rehabilitation strategies in patients with head-and-neck cancers treated with surgery, radiotherapy, and chemotherapy: a critical review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.018

Oropharyngeal carcinoma related to human papillomavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.018

HPV infections and tonsillar carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.018

U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.018

Anal intraepithelial neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.018

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.018

Anal squamous intraepithelial lesions and condyloma in HIV-infected heterosexual men, homosexual men and women: prevalence and associated factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.018

[Cervical cancer screening and associated treatment costs in France]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.018

The costs of head and neck oncology: primary tumours, recurrent tumours and long-term follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.018

Healthcare resource use and costs associated with cervical, vaginal and vulvar cancers in a large U.S. health plan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.018

A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against High-grade Cervical and External Genital Lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.018

Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.018

Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.05.018

10.1016/J.VACCINE.2011.05.018

7 January 2021

Identifiers

DOI

1 reference

25 November 2017

1 reference